The ProteinACCSL: A Potential Drug Target and Biomarker for 1-Aminocyclopropane-1-Carboxylate Synthase-Like Protein 2

Target Name: ACCSL

NCBI ID: G390110

ACCSL

Other Name(s): Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 (isoform X1) | 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like | 1-aminocyclopropane-1-carboxylate synthase homolog (Arabidopsis), transcript variant X1 | 1-aminocyclopropane-1-carboxylate synthase-like protein 2 | ACC synthase-like protein 2 | ACCSL transcript variant X1 | ACCSL variant 1 | ACCSL variant X1 | Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 (isoform 1) | 1-aminocyclopropane-1-carboxylate synthase (inactive)-like, transcript variant X1 | 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like, transcript variant 1 | 1-aminocyclopropane-1-carboxylate synthase homolog (Arabidopsis)(non-functional)-like | 1-aminocyclopropane-1-carboxylate synthase (inactive)-like | Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 | 1-aminocyclopropane-1-carboxylate synthase homolog(non-functional)-like | Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 isoform X1 | 1A1L2_HUMAN

The ProteinACCSL: A Potential Drug Target and Biomarker for 1-Aminocyclopropane-1-Carboxylate Synthase-Like Protein 2

1-Aminocyclopropane-1-carboxylate synthase-like protein 2 (ACCSL) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ACCSL is a key enzyme in the synthesis of 1-aminocyclopropane-1-carboxylate (ACP), a crucial molecule in many cellular processes, including cell signaling, DNA replication, and metabolism. The deregulation of ACCSL has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

The potential drug targets for ACCSL are numerous and varied. One of the primary targets is the inhibition of ACCSL activity, as this would decrease the production of ACP and disrupt cellular processes that are critical for disease progression. This can be achieved through various mechanisms, such as inhibition of the enzyme's catalytic activity, modulation of its stability, or disruption of its subcellular localization.

Another potential drug target for ACCSL is the modulation of its expression levels. This can be achieved through various signaling pathways, such as the TGF-β pathway, which regulates cell growth and differentiation, and the PI3K/AKT pathway, which regulates cell survival and metabolism. Modulation of ACCSL expression levels can lead to decreased or increased production of ACP, which can have a profound impact on cellular processes and disease progression.

Biomarker Potential

ACCSL has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The detection and quantification of ACCSL expression levels in tissues and fluids can provide valuable information about disease status and progression. For example, decreased ACCSL expression has been associated with cancer progression, while increased expression has been implicated in neurodegenerative diseases.

Expression of ACCSL has also been used as a biomarker for evaluating the efficacy of certain therapeutic approaches. For instance, the expression of ACCSL has been shown to be reduced in response to chemotherapy, which suggests that this protein may play a role in the development of resistance to chemotherapy in cancer patients. Similarly, the expression of ACCSL has been shown to be increased in individuals with neurodegenerative diseases, which may be an indicator of the effectiveness of certain therapeutic approaches.

Conclusion

ACCSL is a protein that has been identified as a potential drug target and biomarker for various diseases. The inhibition of its activity or modulation of its expression levels can have a profound impact on cellular processes and disease progression. Further research is needed to fully understand the role of ACCSL in disease progression and the development of new therapeutic approaches.

Protein Name: 1-aminocyclopropane-1-carboxylate Synthase Homolog (inactive) Like

The "ACCSL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACCSL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets